Tesamorelin is a synthetic analogue of the growth hormone-releasing hormone (GHRH) that includes an extra trans-3-hexanoic acid group. Developed by Theratechnologies in Canada, tesamorelin was approved by the FDA in 2010 as a treatment for HIV-associated lipodystrophy. This condition results in abnormal accumulation of fat in the abdomen and other areas of the body, often as a result of antiretroviral therapy.
Before the approval of tesamorelin, patients had few effective treatment options beyond diet and exercise, and surgical intervention was often unsuccessful. Tesamorelin has been found to reduce adiposity by almost 20%, making it significantly more effective than other available treatments.
Currently, tesamorelin is being investigated for its potential to reduce cardiovascular disease in individuals with HIV, promote peripheral nerve regeneration, and slow the progression of mild cognitive impairment (MCI), a precursor to dementia. Ongoing clinical trials are exploring these potential therapeutic applications. As tesamorelin is already approved by the FDA for use in humans, it is a promising subject for continued research.
The primary concern for peptide researchers today is product purity. Nord-sci guarantees our product purity by performing independent testing of our products and providing those certifications for our customers in our product descriptions.
THIS PRODUCT IS NOT INTENDED TO TREAT, CURE OR DIAGNOSE ANY CONDITION OR DISEASE AND IS NOT FOR HUMAN CONSUMPTION.
ALL PRODUCTS OFFERED ARE INTENDED FOR LABORATORY RESEARCH USE ONLY.